Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Alirocumab (Praluent) vs Bempedoic Acid: Alirocumab (Praluent) has the stronger overall evidence (4.5 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Alirocumab (Praluent) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Alirocumab (Praluent) and Bempedoic Acid have evidence — compare verdict strength side-by-side.
Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.
Any time of day
Subcutaneous prefilled pen/syringe (alirocumab)
180 mg orally once daily, with or without food, under a clinician. Available alone (Nexletol) or co-formulated with ezetimibe 10 mg (Nexlizet). A prescription drug — dosing is set by a prescriber.
Any time of day
Oral tablet (bempedoic acid 180 mg)
Within weeks
Months to years
Years
At each injection
Weeks (full effect by ~12 weeks)
Months to years
Throughout use
Weeks to months
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
The New England journal of medicine (2018) · Rct · n=18924
ODYSSEY OUTCOMES randomized trial of ~18,900 patients 1–12 months after acute coronary syndrome on intensive statins
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
The New England journal of medicine (2015) · Rct · n=2341
ODYSSEY LONG TERM randomized trial in high-cardiovascular-risk patients on maximally tolerated statins
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
European heart journal (2015) · Rct · n=735
Pooled ODYSSEY FH I and FH II randomized trials in 735 heterozygous familial-hypercholesterolemia patients
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
The New England journal of medicine (2023) · Rct · n=13970
CLEAR Outcomes: ~13,970 statin-intolerant patients randomized to bempedoic acid 180 mg vs placebo
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
The New England journal of medicine (2019) · Rct · n=2230
CLEAR Harmony: 2,230 patients with ASCVD and/or familial hypercholesterolemia on maximally tolerated statins
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
JAMA (2019) · Rct · n=779
CLEAR Wisdom: 779 high-cardiovascular-risk patients on maximally tolerated statins
Alirocumab (Praluent) has a higher evidence score (4.5/10 vs 4.3/10) and wins in 2 of 3 categories.
For support heart health, Alirocumab (Praluent) has a higher relevance score (80 vs 72).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.